Dr. Jaroslaw Maciejewski (Cleveland Clinic) briefly discusses the diagnosis and treatment of PNH and MDS and the relationship between each disease. He also talks about the biologic significance of the development of PNH clones in MDS and what this means as a prognosis. Specifically, this will involve talking about refractory anemia MDS subgroups and hypoplastic MDS.
By the end of this program, you will understand:
- What PNH clones are what they mean in a diagnosis
- How treatment can be affected
- Hypoplastic MDS and the similarities to aplastic anemia and implications to PNH.